Spots Global Cancer Trial Database for Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies
Official Title: A Phase 1/1b Study of Paclitaxel in Combination With BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients With Advanced Nonhaematologic Malignancies
Study ID: NCT03328494
Conditions
Study Description
Brief Summary: This study will be conducted to assess the safety and tolerability of BOS172722 when administered as monotherapy and in combination with paclitaxel in participants with advanced nonhaematologic malignancies and also to establish the maximum tolerated dose and recommended Phase 2 dose of BOS172722 in combination with paclitaxel in those participants.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Addenbrooks Hospital, Cambridge, , United Kingdom
Edinburgh Cancer Centre - Western General Hospital, Edinburgh, , United Kingdom
Royal Marsden, London, , United Kingdom
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
